Heat versus drugs in the treatment of benign prostatic hyperplasia

BJU International

Volumn 91, Issue 2, 2003, Pages 131-137

  Djavan, B ^a   Seitz, C ^b   Marberger, M ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; FINASTERIDE; PRAZOSIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN;

ASTHENIA; CATHETERIZATION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EJACULATION DISORDER; EPIDIDYMITIS; HEADACHE; HEALTH CARE COST; HEMATURIA; HEMOSPERMIA; HUMAN; HYPOTENSION; INTERMETHOD COMPARISON; MALE; META ANALYSIS; NAUSEA; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; TRANSURETHRAL MICROWAVE THERMOTHERAPY; URINARY TRACT INFECTION; URINE FLOW RATE; URINE RETENTION; VERTIGO; XEROSTOMIA; ADJUVANT THERAPY; ALPHA ADRENERGIC RECEPTOR BLOCKING; MICTURITION; PATIENT SELECTION;

ADRENERGIC ALPHA-ANTAGONISTS; CATHETERIZATION; COMBINED MODALITY THERAPY; HUMANS; HYPERTHERMIA, INDUCED; MALE; MICROWAVES; PATIENT SELECTION; PROSTATIC HYPERPLASIA; TESTOSTERONE 5-ALPHA-REDUCTASE; TREATMENT OUTCOME;

EID: 0037232349     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2003.03034.x     Document Type: Review

References (56)

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-9
2. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338: 469-71
3. Glynn RJ, Campion EW, Bouchard GR, Silbert JE. The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study. Am J Epidemiol 1985; 121: 78-90
4. Mebust WK, Holtgrewe HL, Cockett ATK, Peters PC. Transurethral prostatectomy. immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol 1989; 141: 243-7
5. Doll HA, Black NA, McPherson K, Flood AB, Williams GB, Smith JC. Mortality, morbidity and complications following transurethral resection of the prostate for benign prostatic hypertrophy. J Urol 1992; 147: 1566-73
6. Neal DE, Ramsden PD, Sharples L et al. Outcome of elective prostatectomy. BMJ 1989; 299: 762-7
7. Nielsen KT, Christensen MM, Madsen PO, Bruskewitz RC. Symptom analysis and uroflowmetry 7 years after transurethral resection of the prostate. J Urol 1989; 142: 1251-3
8. Roos NP, Wennberg JE, Malenka DJ et al. Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia. N Engl J Med 1989; 320: 1120-4
9. Ahlstrand C, Carlsson P, Jonsson B. An estimate of the life-time cost of surgical treatment of patients with benign prostatic hyperplasia in Sweden. Scand J Urol Nephrol 1996; 30: 37-43
10. Caine M, Pfau A, Perlberg S. The use of alpha-adrenergic blockers in benign prostatic obstruction. Br J Urol 1976; 48: 255-63
11. Caine M, Perlberg S, Meretyk S. A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol 1978; 50: 551-4
12. Barry MJ, Fowler FJ, Bin L, Oesterling JE. A nationwide survey of practicing urologists: current management of benign prostatic hyperplasia and clinically localized prostate cancer. J Urol 1997; 158: 488-91
13. Stoner E. The clinical development of a 5 alpha-reductase inhibitor, finasteride. J Steroid Biochem Mol Biol 1990; 37: 375-8
14. de la Rosette JJMCH, D'Ancona FCH, Debruyne FMJ. Current status of thermotherapy of the prostate. J Urol 1997; 157: 430-8
15. Djavan B, Madersbacher S, Klingler HC, Ghawidel K, Hruby S, Seitz C. Outcome analysis of minimally invasive treatments for benign prostatic hyperplasia. Tech Urol 1999; 5: 12-20
16. Osman Y, Larson T. Correlation between MRI gadolinium central zone perfusion defects and intra-prostatic temperatures during transurethral microwave thermotherapy (Abstract). World Congress of Endourology, Rhodes, Greece, September 2, 1999: A17
17. Larson TR, Bostwick DG, Corica A. Temperature-correlated histopathologic changes following microwave thermoablation of obstructive tissue in patients with benign prostatic hyperplasia. Urology 1996; 47: 463-9
18. Netto NR, Claro JA. Traitement de l'hypertrophie bénigne de prostate par Prostatron®: étude des effets d'une augmentation de la température de traitement. Prog Urol 1995; 5: 238-44
19. Larson TR, Collins JM, Corica A. Detailed interstitial temperature mapping during treatment with a novel transurethral microwave thermoablation system in patients with benign prostatic hyperplasia. J Urol 1998; 159: 258-64
20. Larson TR, Blute ML, Tri JL, Whitlock SV. Contrasting heating patterns and efficiency of the Prostatron and Targis microwave antennae for thermal treatment of benign prostatic hyperplasia. Urology 1998; 51: 908-15
21. Bdesha AS, Bunce CJ, Snell ME, Witherow RO. A sham controlled trial of transurethral microwave therapy with subsequent treatment of the control group. J Urol 1994; 152: 453-8
22. de la Rosette JJMCH, de Wildt MJAM, Alivizatos G, Froeling FMJA, Debruyne FMJ. Transurethral microwave thermotherapy (TUMT) in benign prostatic hyperplasia: placebo versus TUMT. Urology 1994; 44: 58-63
23. Blute ML, Patterson DE, Segura JW, Tomera KM, Hellerstein DK. Transurethral microwave thermotherapy v sham treatment: double-blind randomized study. J Endourol 1996; 10: 565-73
24. de Wildt MJAM, Hubregtse M, Ogden C, Carter SSC, Debruyne FMJ, de la Rosette JJMCH. A 12-month study of the placebo effect in transurethral microwave thermotherapy. Br J Urol 1996; 77: 221-7
25. Larson TR, Blute ML, Bruskewitz RC, Mayer RD, Ugarte RR, Utz WJ. A high-efficiency microwave thermoablation system for the treatment of benign prostatic hyperplasia: results of a randomized, sham-controlled, prospective, double-blind, multicenter clinical trial. Urology 1998; 51: 731-42
26. Roehrborn CG, Preminger G, Newhall P et al. Microwave thermotherapy for benign prostatic hyperplasia with the Dornier Urowave. Results of a randomized, double-blind, multicenter, sham-controlled trial. Urology 1998; 51: 19-28
27. Djavan B, Ghawidel K, Basharkhah A, Seitz C, Remzi M, Ghawidel K. Pretreatment prostate-specific antigen as an outcome predictor of targeted transurethral microwave thermotherapy. Urology 2000; 55: 51-7
28. Ramsey EW, Miller PD, Parsons K. A novel transurethral microwave thermoablation system to treat benign prostatic hyperplasia. results of a prospective multicenter clinical trial. J Urol 1997; 158: 112-9
29. Djavan B, Fakhari M, Shariat S, Ghawidel K, Marberger M. A novel intraurethral prostatic bridge catheter for prevention of temporary prostatic obstruction following high energy transurethral microwave thermotherapy in patients with benign prostatic hyperplasia. J Urol 1999; 161: 144-51
30. Ramsey EW, Miller PD, Parsons K. Transurethral microwave thermotherapy in the treatment of benign prostatic hyperplasia: results obtained with the Urologix T3 device. World J Urol 1998; 16: 96-101
31. Cormio L, Bloem F, Laduc R, Debruyne FMJ. Pain sensation in transurethral microwave thermotherapy for benign prostatic hyperplasia: the rationale for prophylactic sedation. Eur Urol 1994; 25: 36-9
32. Djavan B, Shariat S, Schäfer B, Marberger M. Tolerability of high energy transurethral microwave thermotherapy with topical urethral anesthesia: results of a prospective, randomized, single-blinded clinical trial. J Urol 1998; 160: 772-6
33. Ahmed M, Bell T, Lawrence WT, Ward JP, Watson GM. Transurethral microwave thermotherapy (Prostatron™, version 2.5. compared with transurethral resection of the prostate for the treatment of benign prostatic hyperplasia: a randomized, controlled, parallel study. Br J Urol 1997; 79: 181-5
34. 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36: 1-13
35. D'Ancona FCH, Francisca EAE, Witjes WPJ, Welling L, Debruyne FMJ, De La Rosette JJMCH. Transurethral resection of the prostate vs high-energy thermotherapy of the prostate in patients with benign prostatic hyperplasia: long-term results. Br J Urol 1998; 81: 259-64
36. De La Rosette JJMCH, De Wildt MJAM, Hofner K, Carter SSC, Debruyne FMJ, Tubaro A. High energy thermotherapy in the treatment of benign prostatic hyperplasia: results of the European benign prostatic hyperplasia study group. J Urol 1996; 156: 97-102
37. De Wildt MJAM, Debruyne FMJ, De La Rosette JJMCH. High energy transurethral microwave thermotherapy: a thermoablative treatment for benign prostatic obstruction. Urology 1996; 48: 416-23
38. De La Rosette JJMCH, De Wildt MJAM, Hofner K, Carter SSC, Debruyne FMJ, Tubaro A. Pressure/flow study analyses in patients treated with high-energy thermotherapy. J Urol 1996; 156: 1428-33
39. D'Ancona FCH, Franciska EAE, Hendriks JCM, Debruyne FMJ, De La Rosette JJMCH. The predictive value of baseline variables in the treatment of benign prostatic hyperplasia using high-energy transurethral microwave thermotherapy. Br J Urol 1998; 82: 808-13
40. D'Ancona FCH, Franciska EAE, Witjes WPJ, Welling L, Debruyne FMJ, De La Rosette JJMCH. High energy thermotherapy (TUMT) versus transurethral resection (TURP) in the treatment of benign prostatic hyperplasia (BPH): results of a prospective randomized study with a one year follow-up. J Urol 1997; 158: 120-5
41. Walden M, Acosta S, Carlsson P, Pettersson S, Dahlstrand C. A cost-effectiveness analysis of transurethral resection of the prostate and transurethral microwave thermotherapy for treatment of benign prostatic hyperplasia: two-year follow-up. Scand J Urol Nephrol 1997; 32: 204-10
42. Chirikos TN, Sanford E. Cost consequences of surveillance, medical management or surgery for benign prostatic hyperplasia. J Urol 1996; 155: 1311-6
43. Djavan B, Roehrborn CG, Shariat S, Ghawidel K, Marberger M. Prospective randomized comparison of high energy transurethral microwave thermotherapy versus α-blocker treatment of patients with benign prostatic hyperplasia. J Urol 1999; 161: 139-43
44. Mobley DF, Dias N, Levenstein M. Effects of doxazosin in patients with mild, intermediate, and severe benign prostatic hyperplasia. Clin Ther 1998; 20: 101
45. Hansen BJ, Nordling J, Mensink HJ, Walter S, Meyhoff HH, and the ALFECH Study Group. Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual: a multicentre, double-blind, placebo-controlled trial. Scand J Urol Nephrol Suppl 1994; 157: 169
46. Jardin A, Bensadoun H, Delauche-Cavallier MC, Attali P and the BPH-ALF Group. Alfuzosin for treatment of benign prostatic hypertrophy. Lancet 1991; 337: 1457
47. Tenover JL, Pagano GA, Morton AS, Liss CL, Byrnes CA. and Group ftPCIS. Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: a primary care study. Clin Ther 1997; 19: 243-58
48. Roehrborn CG, Siegel RL. Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. Urology 1996; 48: 406
49. Lukacs B, Blondin P, MacCarthy C, Du Boys B, Grippon P, Lassale C. Safety profile of 3 months' therapy with alfuzosin in 13,389 patients suffering from benign prostatic hypertrophy. Eur Urol 1996; 29: 29
50. Lukacs B, Grange JC, McCarthy C, Comet D. Clinical uroselectivity: a 3-year follow-up in general practice. Eur Urol 1998; 33 (Suppl. 2): 28
51. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996; 48: 398-405
52. Djavan B, Seitz C, Roehrborn C et al. Targeted transurethral microwave thermotherapy vs. α-blockade in benign prostatic hyperplasia (BPH): outcomes at 18 months. Urology 2001; 57: 66-70
53. Djavan B, Shariat S, Fakhari M. Neoadjuvant and adjuvanta-blockade improves early results of high-energy transurethral microwave thermotherapy for lower urinary tract symptoms of benign prostatic hyperplasia: a randomized, prospective clinical trial. Urology 1999; 53: 251-9
54. Andersen J, Nickel J, Marshall V, Schulman CC, Boyle P. Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology 1997; 49: 839-45
55. Lukacs B, Grange J, Comet D, McCarthy C and the BPH Group in General Practice. Three years prospective study of 3228 clinical BPH patients treated with alfuzosin in General Practice. Prostate Cancer Prostate Dis 1998; 5: 276-83
56. DeWildt M, D'Ancona F, Hubregtse M, Carter S, Debruyne F, de la Rosette JJMCH. Three year follow up of patients treated with lower energy microwave therapy. J Urol 1996; 156: 159-64